Tweet

Novartis Animal Health: Changes To The Supply Of Acepromazine (ACP)

Author: Novartis Animal Health
Posted: Wednesday 29th December, 2010. 11:00:56

Recent upgrades to Novartis Animal Health’s manufacturing plant in the UK have resulted in the site becoming a worldwide centre of excellence for the production of bulk liquids. This upgrade has had an impact on the manufacture of ACP 2mg/ml and 10mg/ml injectable products, which will no longer be produced in the UK.

From January 2011, Novartis Animal Health will no longer be able to supply ACP Injection 2mg/ml or ACP Injection 10mg/ml to wholesalers. However, it is not Novartis’ intention to discontinue the supply of acepromazine injectable; in order to ensure consistency of supply to the UK market the company will be importing the Vetoquinol French product Calmivet.

Calmivet is a monovalent acepromazine injection licensed for use in dogs, cats and horses, available as a 5mg/ml injection, 50ml vial.

In order to obtain Calmivet from wholesalers, veterinarians will need to apply for a free of charge Special Import Certificate from the VMD. This can be completed online at www.vmd.gov.uk.

It is anticipated that this situation will continue for at least the first six months of 2011, until an alternative manufacturing site able to produce ACP injectable is established. As soon as we have more information on the timelines this will be communicated.

A letter advising veterinarians of this change, along with a prep room reminder poster and Calmivet product leaflet has been mailed to all UK practices. If you have not yet received this mailing please contact your Novartis Territory Manager.

Vetoquinol UK are not responsible for the distribution or technical support of this product, so any queries arising from this change should be directed to Technical Services at Novartis Animal Health UK on 01276 694402.

The production and supply of ACP Tablets 10mg remains unaffected.

This article has been viewed 5653 times.

 

Comments about this article